Moderna wants to extent its European footprint
The former mRNA start-up Moderna Inc is set to expand its commercial network in six European nations to become a gobally active vaccine company.
ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2082 entries already.
The former mRNA start-up Moderna Inc is set to expand its commercial network in six European nations to become a gobally active vaccine company.
Antimicrobial resistance specialist Centauri Therapeutics Ltd has closed a £24m Series A round to identify novel therapeutic candidates using the Alphamer technology.
Curve Therapeutics has inked a contract with US pharma giant Merck & Co. (MSD) to screen novel small molecule drug candidates against five MSD targets.
Newton Biocapital has launched a new life sciences fund with initial capital commitments of €50m and a target size of €150m.
European investment firm LSP has closed its European life sciences fund LSP at €1 bn. Additionally, a €10bn fund of funds was greenlighted at the EU Council in Paris.
AiCuris will pay up to €100m to Dutch Hybridize Therapeutics BV for the development of antisense RNA therapeutics that stop BK viraemia in renal transplant patients.
AGC Biologics supports BioNTech’s manufacturing of an Omicron-based vaccine with plasmids for in vitro transcription.
EU Members States agreed on Tuesday to launch the pan-European Scale-up Initiative, which is aimed to provide €10bn for late-state tech companies.
Dutch insect protein specialist Protix has raised €50m for expansion and development from international investors and the ECBF.
A rapid antigen test provides a fast and reliable indication of the presence of the SARS-CoV-2 virus, the causative agent of Covid-19. A positive result of an antigen test is reliable, whereas a negative result does not completely rule out infection with the SARS-CoV-2 virus. The success of rapid tests is therefore limited by the sensitivity of the antibodies used.